Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - Ασθμα - Φάρμακα αποφρακτικών παθήσεων των αναπνευστικών οδών, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - Αναιμία, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - Παράγοντες τροποποίησης λιπιδίων - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - Η Σκλήρυνση Κατά Πλάκας, Υποτροπιάζουσα-Διαλείπουσα - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - everolimus - tablets - 0.25mg - everolimus (8000002059) 0,25mg - everolimus

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - everolimus - tablets - 1mg - everolimus (8000002059) 1mg - everolimus

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - everolimus - tablets - 0.5mg - everolimus (8000002059) 0,5mg - everolimus

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - everolimus - tablets - 0.75mg - everolimus (8000002059) 0,75mg - everolimus

Կիպրոս - հունարեն - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

novartis ireland limited (0000010772) vista building, elm park, merrion road, ballsbridge, dublin, dublin 4 - valsartan - film coated tablets - 40mg - valsartan (8000001531) 40mg - valsartan